(Q44611540)

4 December 2017

title

Vincristine, irinotecan, and temozolomide in patients with relapsed and refractory Ewing sarcoma (English)

1 reference

4 December 2017

0 references

1 reference

4

Radoslaw Chaber

1 reference

4 December 2017

3

Katarzyna Drabko

1 reference

4 December 2017

1

Anna Raciborska

1 reference

4 December 2017

2

Katarzyna Bilska

1 reference

4 December 2017

5

Monika Pogorzala

1 reference

4 December 2017

Elżbieta Wyrobek

6

1 reference

4 December 2017

Katarzyna Polczyńska

7

1 reference

4 December 2017

Elżbieta Rogowska

8

1 reference

4 December 2017

Carlos Rodriguez-Galindo

9

1 reference

4 December 2017

Wojciech Wozniak

10

1 reference

4 December 2017

publication date

15 June 2013

1 reference

4 December 2017

published in

Pediatric Blood Cancer

1 reference

4 December 2017

volume

60

1 reference

4 December 2017

issue

10

1 reference

4 December 2017

page(s)

1621-1625

1 reference

Analysis of prognostic factors in ewing sarcoma family of tumors: review of St. Jude Children's Research Hospital studies

4 December 2017

cites work

1 reference

Results of the EICESS-92 Study: two randomized trials of Ewing's sarcoma treatment--cyclophosphamide compared with ifosfamide in standard-risk patients and assessment of benefit of etoposide added to standard treatment in high-risk patients

21 January 2018

1 reference

Primary disseminated multifocal Ewing sarcoma: results of the Euro-EWING 99 trial.

21 January 2018

1 reference

Outcome after relapse in an unselected cohort of children and adolescents with Ewing sarcoma.

21 January 2018

1 reference

Prognostic factors for patients with Ewing sarcoma (EWS) at first recurrence following multi-modality therapy: A report from the Children's Oncology Group

21 January 2018

1 reference

Temozolomide and intravenous irinotecan for treatment of advanced Ewing sarcoma

21 January 2018

1 reference

Irinotecan and temozolomide for Ewing sarcoma: the Memorial Sloan-Kettering experience

21 January 2018

1 reference

Temozolomide in resistant or relapsed pediatric solid tumors

21 January 2018

1 reference

Camptothecin-based regimens for treatment of ewing sarcoma: past studies and future directions

21 January 2018

1 reference

Randomized Phase II Window Trial of Two Schedules of Irinotecan With Vincristine in Patients With First Relapse or Progression of Rhabdomyosarcoma: A Report From the Children's Oncology Group

21 January 2018

1 reference

Safety assessment of intensive induction with vincristine, ifosfamide, doxorubicin, and etoposide (VIDE) in the treatment of Ewing tumors in the EURO-E.W.I.N.G. 99 clinical trial

21 January 2018

1 reference

Survival after recurrence of Ewing's sarcoma family of tumors

21 January 2018

1 reference

Topotecan and cyclophosphamide in patients with refractory or relapsed Ewing tumors.

21 January 2018

1 reference

Does consolidation with autologous stem cell transplantation improve the outcome of children with metastatic or relapsed Ewing sarcoma?

21 January 2018

1 reference

Response to high-dose ifosfamide in patients with advanced/recurrent Ewing sarcoma

21 January 2018

1 reference

Ifosfamide, carboplatin, and etoposide (ICE) reinduction chemotherapy in a large cohort of children and adolescents with recurrent/refractory sarcoma: the Children's Cancer Group (CCG) experience

21 January 2018

1 reference

Carboplatin-based chemotherapy for refractory and recurrent Ewing's tumours

21 January 2018

1 reference

Topotecan by 21-day continuous infusion in children with relapsed or refractory solid tumors: a Children's Oncology Group study

21 January 2018

1 reference

A phase II study of imatinib mesylate in children with refractory or relapsed solid tumors: a Children's Oncology Group study.

21 January 2018

1 reference

Gemcitabine and docetaxel (GEMDOX) for the treatment of relapsed and refractory pediatric sarcomas

21 January 2018

1 reference

Treatment of relapsed/refractory pediatric sarcomas with gemcitabine and docetaxel.

21 January 2018

1 reference

Phase II study of sequential gemcitabine followed by docetaxel for recurrent Ewing sarcoma, osteosarcoma, or unresectable or locally recurrent chondrosarcoma: results of Sarcoma Alliance for Research Through Collaboration Study 003.

21 January 2018

1 reference

Consolidation of first-line therapy with busulphan and melphalan, and autologous stem cell rescue in children with Ewing's sarcoma.

21 January 2018

1 reference

Preliminary efficacy of the anti-insulin-like growth factor type 1 receptor antibody figitumumab in patients with refractory Ewing sarcoma

21 January 2018

1 reference

R1507, a monoclonal antibody to the insulin-like growth factor 1 receptor, in patients with recurrent or refractory Ewing sarcoma family of tumors: results of a phase II Sarcoma Alliance for Research through Collaboration study

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1002/PBC.24621

1 reference

4 December 2017

1 reference